logo
logo

Second Sight Medical Products Announces Year Three Nih Funding Of Its Orion Study

Second Sight Medical Products Announces Year Three Nih Funding Of Its Orion Study

05/13/21, 10:04 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svglos angeles
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant UH3NS103442. The NIH released $1.4 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial

Company Info

Company
Second Sight Medical Products
Location
los angeles, california, united states
Additional Info
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at secondsight.com.